Comparative Pharmacology
Head-to-head clinical analysis: PHENYTEK versus PROMPT PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYTEK versus PROMPT PHENYTOIN SODIUM.
PHENYTEK vs PROMPT PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by promoting sodium efflux and inhibiting calcium influx, thereby reducing repetitive firing of action potentials. Enhances GABA-mediated inhibition and modulates voltage-gated sodium channels.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, thereby reducing repetitive firing of action potentials and inhibiting the spread of seizure activity.
Initial dose: 100 mg orally 3 times daily; maintenance: 300-400 mg/day in 3-4 divided doses. Extended-release (ER) formulation: 300 mg orally once daily for once-daily dosing; may be increased to 400 mg once daily if needed.
Loading dose: 15-20 mg/kg (max 1500 mg) IV at a rate not exceeding 50 mg/min. Maintenance dose: 300-600 mg/day IV or orally in 3 divided doses. Adjust per therapeutic drug monitoring (target total phenytoin 10-20 mcg/mL).
None Documented
None Documented
Terminal elimination half-life averages 22 hours (range 7-42 hours). Dose-dependent due to saturable metabolism; half-life increases with higher doses or in hepatic impairment.
30-100 hours (average 40 hours) following IV administration; prolonged in hepatic impairment, neonates, and with enzyme inhibitors; shorter in children and with enzyme inducers.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Renal excretion of inactive metabolites accounts for ~70-80%, with biliary/fecal elimination of ~20%.
Primarily hepatic metabolism (CYP2C9) to inactive p-HPPH. Renal excretion as p-HPPH glucuronide (~60-70%) and unchanged drug (5%), with ~30% biliary/fecal elimination.
Category C
Category D/X
Anticonvulsant
Anticonvulsant